Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-Year results of the rapamune maintenance regimen study

Transplantation

Volumn 76, Issue 2, 2003, Pages 364-370

  Oberbauer, Rainer ^a   Kreis, Henri ^b   Johnson, Robert W G ^c   Mota, Alfredo ^d   Claesson, Kerstin ^e   Ruiz, Juan Carlos ^f   Wilczek, Henryk ^g   Jamieson, Neville ^h   Henriques, Antonio C ⁱ   Paczek, Leszek ^j   Chapman, Jeremy ^k   Burke, James T ^l  

^a UNIVERSITY OF VIENNA   (Austria)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^d CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^e UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^f HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^g KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^h UNIVERSITY OF CAMBRIDGE   (United Kingdom)

ⁱ HOSPITAL DE SANTO ANTÓNIO   (Portugal)

^j MEDICAL UNIVERSITY OF WARSAW   (Poland)

^k WESTMEAD HOSPITAL   (Australia)

^l Clinical Research and Development   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; CREATININE; CYCLOSPORIN A; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RAPAMYCIN; STEROID; TRIACYLGLYCEROL;

ABNORMAL WOUND HEALING; ACUTE GRAFT REJECTION; ADULT; CADAVER DONOR; CANCER; CATARACT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYCLOSPORIN A NEPHROTOXICITY; DRUG WITHDRAWAL; EDEMA; GRAFT SURVIVAL; HERPES ZOSTER; HUMAN; HYPERTENSION; HYPERURICEMIA; HYPOKALEMIA; ILEUS; INFECTION; KIDNEY ALLOGRAFT; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LIPOPROTEIN BLOOD LEVEL; LIVER DYSFUNCTION; LIVING DONOR; LYMPHOMA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NEPHROTOXICITY; PNEUMONIA; POSTTRANSPLANTATION LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN CANCER; SURVIVAL RATE; SYSTOLIC BLOOD PRESSURE; THROMBOCYTOPENIA; TRIACYLGLYCEROL BLOOD LEVEL; WOUND HEALING;

BLOOD PRESSURE; CREATININE; CYCLOSPORINE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HEMOGLOBINS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY TRANSPLANTATION; SIROLIMUS; TREATMENT OUTCOME;

EID: 10744231651     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000074360.62032.39     Document Type: Conference Paper

References (16)

1. Hariharan S, Johson CP, Bresnahan BA, et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 1999; 342: 605.
2. Geddes CC, Cole E, Wade J, et al. Factors influencing long-term primary cadaveric kidney transplantation: importance of functional renal mass versus avoidance of acute rejections - the Toronto Hospital experience 1985-1997. In: Cecka JM, Terasaki PI, eds. Clinical Transplants 1997. Los Angeles, UCLA Tissue Typing Laboratory 1998, p 195.
3. Hariharan S, McBride MA, Cherikh WS, et al. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int 2002; 62: 311.
4. Opelz G, Wujciak T, Ritz E. Association of chronic kidney graft failure with recipient blood pressure. Kidney Int 1998; 53: 217.
5. Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. Lancet 2000; 356: 194.
6. MacDonald AS for The Rapamune Global Study Group. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001; 71: 271.
7. Reitamo S, Spuls P, Sassolas B, et al. Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial. Br J Dermatol 2001; 145: 438.
8. Groth CG, Bäckman L, Morales JM, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Transplantation 1999; 67: 1036.
9. Kreis H, Cisterne JM, Land W, et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000; 69: 1252.
10. Morales JM, Wramner L, Kreis H, et al. Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients. Am J Transplant 2002; 2: 436.
11. Flechner SM, Goldfarb DA, Modlin C, et al. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 2002; 74: 1070.
12. Kasiske BL, Chakkera HA, Louis TA, et al. A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol 2000; 11: 1910.
13. Johnson RWG, Kreis H, Oberbauer R, et al. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 2001; 72: 777.
14. Nankivell BJ, Gruenewald SM, Allen RD, et al. Predicting glomerular filtration rate after kidney transplantation. Transplantation 1995; 59: 1683.
15. Solez K, Axelsen RA, Benediktsson H, et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int 1993; 44: 411.
16. Neumayer HH. Everolimus (RAD, Certican) clinical trials: current results. Abstract 114. Transplantation 2002; 74(suppl): 52.